SITC 2016 Annual Meeting & Associated Programs
SITC 2016 Annual Meeting & Associated Programs

Society for Immunotherapy of Cancer (SITC)

2016 Annual Meeting & Associated Programs

Enduring Materials

Access slide decks and video via the links in the schedule below.

PDF = Click on presentation title to view .pdf version of slides

VIDEO = Presentation video is available; click on the icon to view 

Program Schedule

Friday, November 11, 2016
 

7:30 a.m. – 7:35 a.m. Presidential Welcome
Howard L. Kaufman, MD, FACS – Rutgers Cancer Center Institute of New Jersey
7:35 a.m. – 8:00 a.m. Holbrook Edwin Kidd Kohrt, MD, PhD Tribute*
Non-CE Session
Co-Chairs:
Daniel S. Chen, MD, PhD – Genentech
Amani Makkouk, PhD – Calithera Biosciences
Ignacio Melero, MD, PhD – University of Navarra
Russell Pachynski, MD – Washington University School of Medicine

Update Session: Cancer Immunotherapy Trials Network (CITN): Ten Trials with High Priority Agents in Twenty Five Minutes
 

0.25 AMA PRA Category 1 CreditsTM
Chair:
Martin Cheever, MD – Fred Hutchinson Cancer Research Center
8:00 a.m. – 8:05 a.m. Anti-PD1 in Merkel Cell Cancer and in Malignancy with HIV, IL7 in Prostate Cancer, Anti-CD40 in Pancreas Cancer
Martin Cheever, MD – Fred Hutchinson Cancer Research Center
8:05 a.m. – 8:10 a.m. Anti-PD1 in Mycosis Fungoides/Sezary Syndrome
Michael Khodadoust, MD – Stanford University
8:10 a.m. – 8:15 a.m. IL15 in Solid Tumors
Jeffrey S. Miller, MD – University of Minnesota
8:15 a.m. – 8:20 a.m. IDO Inhibitor in Ovarian Cancer and Melanoma
Kunle Odunsi, MD, PhD – Roswell Park Cancer Institute Center for Immunotherapy
8:20 a.m. – 8:25 a.m. Flt3-L with Poly ICLC and Anti-DEC205-NY-ESO-1 in Melanoma
Nina Bhardwaj, MD, PhD – The Tisch Cancer Institute at The Mount Sinai Medical Center

Keynote Address
 

Non-CE Session
8:25 a.m. – 8:30 a.m. Introduction
Howard L. Kaufman, MD, FACS – Rutgers Cancer Center Institute of New Jersey
8:30 a.m. – 9:05 a.m. The Mechanistic Basis of Cancer Immunotherapy
Ira Mellman, PhD – Genentech
9:05 a.m. – 9:10 a.m. Question & Answer
Ira Mellman, PhD – Genentech

Tumor Microenvironment
 

2.25 AMA PRA Category 1 Credits™
Co-Chairs:

Mary L. (Nora) Disis, MD – University of Washington
Thomas F. Gajewski, MD, PhD – University of Chicago
9:10 a.m. – 9:15 a.m. Introduction  VIDEO
Co-Chair & Faculty: Mary (Nora) L. Disis, MD – University of Washington
9:15 a.m. – 9:40 a.m. Tumor Microenvironment with Clinical Aspect; Impact of Therapeutics on Microenvironment
George Coukos, MD, PhD – University Hospital of Lausanne
9:40 a.m. – 10:05 a.m. Immunomodulatory Roles of Lymphatic Vessels in the Tumor Microenvironment
Melody Swartz, PhD – University of Chicago
10:25 a.m. – 10:50 a.m. CD4 T Cells as Regulators of Tumor Growth  VIDEO
Mary (Nora) L. Disis, MD – University of Washington
10:50 a.m. – 11:05 a.m. Neuropilin-1-Deficient Regulatory T Cell-Derived Interferon-γ Drives Infectious Instability and Tumor Clearance
Abigail E. Overacre – University of Pittsburgh
11:05 a.m. – 11:30 a.m. Tumor and Host Factors Influencing Immune Regulation Within the Tumor Microenvironment
Thomas F. Gajewski, MD, PhD – University of Chicago
11:30 a.m. – 11:45 a.m. CD8α+ Dendritic Cells Regulate Leukemia Antigen-Specific CD8+ T Cell Tolerance  PDF  VIDEO
Justin P. Kline, MD – University of Chicago

Late-Breaking Abstract Session I
 

Non-CE Session
Chair:
Laura S. Wood, RN, MSN OCN – Cleveland Clinic Taussig Cancer Institute
11:45 a.m. – 12:00 a.m. Computational Identification, Functional Characterization and Antibody Blockade of a New Immune Checkpoint in the TIGIT Family of Interacting Molecules  PDF  VIDEO
John Hunter, PhD – Compugen USA, Inc.
12:00 p.m. – 12:15 p.m. Combinatorial CD8+ and PD-L1 + Cell Densities Correlate with Response and Improved Survival in NSCLC Patients Treated with Durvalumab  PDF  VIDEO
Sonja Althammer, PhD – Definiens AG

Update Session: Government Agencies
 

0.5 AMA PRA Category 1 Credits™
Chair:
James L. Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Health
1:30 p.m. – 1:45 p.m. National Cancer Institute
T. Kevin Howcroft, PhD – National Cancer Institute, National Institutes of Health
1:45 p.m. – 2:00 p.m. U.S. Food & Drug Administration
Raj K. Puri, MD, PhD – U.S. Food & Drug Administration

State-of-the-Art Immunotherapies: Challenges and Opportunities
 

2.25 AMA PRA Category 1 Credits™
Co-Chairs:

James L. Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Health
Roy S. Herbst, MD, PhD – Yale Cancer Center
2:00 p.m. –  2:05 p.m. Introduction
James L. Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Heath
2:05 p.m. – 2:30 p.m. Challenges and Opportunities for Immunotherapy in Prostate Cancer  PDF
James L. Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Health
2:30 p.m. – 2:55 p.m. Melanoma: Challenges and Opportunities and the Need for Rational Combinations of Agents  PDF  VIDEO
Patrick Hwu, MD – University of Texas MD Anderson Cancer Center
2:55 p.m. – 3:05 p.m. Phase I/II CANON Study: Oncolytic Immunotherapy for the Treatment of Non-Muscle Invasive Bladder (NMIBC) Cancer Using Intravesical Coxsackievirus A21
Nicola E. Annels, BSc, PhD – University of Surrey
3:05 p.m. – 3:15 p.m.               IL-15 Primes an mTOR-Regulated Gene-expression Program to Prolong Anti-tumor Capacity of Human Natural Killer Cells  PDF  VIDEO
 Andreas Lundqvist – Karolinska Institutet
3:15 p.m. – 3:25 p.m. Reactivating the Anti-Tumor Immune Response by Targeting Innate
and Adaptive Immunity in a Phase I/II Study of Intratumoral IMO-2125
in Combination with Systemic Ipilimumab in Patients with Anti-PD-1
Refractory Metastatic Melanoma
  PDF  VIDEO
Cara Haymaker, PhD – University of Texas MD Anderson Cancer Center
3:25 p.m. – 3:50 p.m. Translational Development of Novel Immunotherapies for Hematologic
Cancers
  PDF  VIDEO
Larry W. Kwak, MD, PhD – City of Hope National Medical Center
3:50 p.m. – 4:15 p.m. Lung Cancer: Frontline Therapy, Predictive Markers, and Novel
Combinations
  PDF  VIDEO
Roy S. Herbst, MD, PhD – Yale Cancer Center

Concurrent Session 1: Metabolic and Age-Associated Dysregulation of Anti-Cancer Immunity
 

1.5 AMA PRA Category 1 Credits™
Organized in collaboration with the American Society for Cell Biology (ASCB)
Co-Chairs:

Tom Misteli, PhD – National Cancer Institute, National Institutes of Health
Graham P. Pawelec, PhD – University of Tuebingen
4:45 p.m. – 4:50 p.m. Introduction  PDF
Graham P. Pawelec, PhD – University of Tuebingen
4:50 p.m. – 5:15 p.m. The Immune System Strikes Back: T Cells Recognizing Indoleamine 2,3-Dioxygenase (IDO) or PD-L1
Mads Hald Andersen, PhD  – Herlev University Hospital
5:15 p.m. – 5:40 p.m. Myeloid-Derived Suppressor Cells (MDSC), Age and Cancer  VIDEO
Dawn Bowdish, PhD – McMaster University
5:40 p.m. – 5:55 p.m. NAD-Sirt1 Axis is Central to the Unique Immuno-Metabolic Phenotype of Th1/17 Hybrid Cells in Regulating its Enhanced Anti-Tumor Potential
Shilpak Chatterjee, PhD – Medical University of South Carolina
5:55 p.m. – 6:10 p.m. The Wnt5a-Beta-Catenin Pathway Triggers a Metabolic Switch that Drives Indoleamine 2,3-Dioxygenase Activity and Dendritic Cell Tolerization in the Melanoma Microenvironment: Optimizing Checkpoint Inhibitor Immunotherapy
Brent A. Hanks, MD, PhD – Duke University Medical Center

Concurrent Session II: Promoting and Measuring Anti-Tumor Immunity
 

1.25 AMA PRA Category 1 Credits™
Co-Chairs:

Francesco M. Marincola, MD – Sidra Medical and Research Center
Jeffrey Schlom, PhD – National Cancer Institute, National Institutes of Health
4:45 p.m. – 4:50 p.m. Introduction
Jeffrey Schlom, PhD – National Cancer Institute, National Institutes of Health
4:50 p.m. – 5:10 p.m. Immunotherapeutics and Analyses of the Peripheral Immunome
Jeffrey Schlom, PhD – National Cancer Institute, National Institutes of Health
5:10 p.m. – 5:30 p.m. Vaccines, Tumor Antigens, and Immune Responses  PDF  VIDEO
Lisa H. Butterfield, PhD – University of Pittsburgh
5:30 p.m. – 5:50 p.m. Deciphering Human T Cell Immune Responses Modulated with Immunotherapy
Lawrence Fong, MD – University of California, San Francisco
5:50 p.m. – 6:05 p.m. Immunoscore® Colon Analytical Performance  VIDEO
Fabienne Hermitte, PhD – HalioDx
6:05 p.m. – 6:10 p.m. Closing Remarks  VIDEO
Francesco M. Marincola, MD – Sidra Medical and Research Center

Saturday, November 12, 2016
 

Update Session: Society Initiatives
 

7:30 AM – 7:40 AM Immune Biomarkers Task Force Update  PDF
Lisa H. Butterfield, PhD – University of Pittsburgh
7:40 AM – 7:55 AM Immunoscore as a Prognostic Marker in Stage I-III Colon Cancer: Results of a SITC-Led Global Validation Study
Jérôme Galon, PhD – INSERM – Cordeliers Research Center

Richard Smalley, MD Memorial Lectureship
 

.75 AMA PRA Category 1 Credits™
7:55 a.m. – 8:00 a.m. Introduction
Howard L. Kaufman, MD, FACS – Rutgers Cancer Center Institute of New Jersey
8:00 a.m. – 8:35 a.m. Smalley Keynote Address: PD-1 Blockade in Cancer Treatment  Immunotherapy Meets Precision Medicine  VIDEO
Suzanne L. Topalian, MD – Johns Hopkins University
8:35 a.m. – 8:40 a.m. Question & Answer
Suzanne L. Topalian, MD – Johns Hopkins University

Beyond Single-Agents: The Future of Combination Immunotherapy
 

2.0 AMA PRA Category 1 Credits™
Co-Chairs:

Drew M. Pardoll, MD, PhD – Johns Hopkins University
F. Stephen Hodi, MD – Dana-Farber Cancer Institute
Holbrook E. Kohrt, MD, PhD– Stanford Cancer Institute*
8:40 a.m. – 8:45 a.m. Introduction
F. Stephen Hodi, MD – Dana-Farber Cancer Institute
8:45 a.m. – 9:10 a.m. Combination Development
Ignacio Melero, MD, PhD – University of Navarra
9:10 a.m. – 9:35 a.m. Next Generation Anti-CTLA-4 Antibodies
Alan J. Korman, PhD – Bristol-Myers Squibb Company
9:35 a.m. – 10:00 a.m. Combination in Patient Selection
Jérôme Galon, PhD – INSERM – Cordeliers Research Center
10:20 a.m.– 10:40 a.m. Combinations and Influences on Biomarkers
Drew M. Pardoll, MD, PhD – Johns Hopkins University
10:40 a.m. – 10:55 a.m. Clinical Safety and Efficacy Assessment of the CD137 Agonist Urelumab Alone and in Combination with Nivolumab in Patients with Hematologic and Solid Tumor Malignancies
Erminia Massarelli, MD – MD Anderson Cancer Center, University of Texas
10:55 a.m. – 11:10 a.m. Beyond Immune Checkpoint: First-in-Class Antibody Targeting Soluble NKG2D Ligand sMIC for Cancer Immunotherapy
Jennifer Wu, PhD – Medical University of South Carolina
11:10 a.m. – 11:15 a.m. Closing Remarks
Drew M. Pardoll, MD, PhD – Johns Hopkins University

Late-Breaking Abstract Session II
 

Non-CE Session
Chair: Elizabeth A. Repasky, PhD – Roswell Park Cancer Institute
11:15 a.m. – 11:30 a.m. Preliminary Efficacy from a Phase 1/2 Study of the Natural Killer Cell-Targeted Antibody, Lirilumab in Combination with Nivolumab in Squamous Cell Carcinoma of the Head and Neck  PDF  VIDEO
Rom Leidner, MD – Earl A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Center
11:30 a.m. – 11:45 a.m. Efficacy and Safety of Nivolumab Plus Ipilimumab in Metastatic Urothelial Carcinoma: First Results From the Phase I/II From the Phase I/II CheckMate 032 Study
Padmanee Sharma, MD, PhD – University of Texas MD Anderson Cancer Center
11:45 a.m. – 12:00 p.m. KEYNOTE-045: Open-label, Phase 3 Study of Pembrolizumab versus Investigator’s Choice of Paclitaxel, Docetaxel, or Vinflunine for Previously Treated Advanced Urothelial Cancer
Joaquim Bellmunt, MD, PhD – Dana-Farber Cancer Institute

Concurrent Session I: Presidential Session
 

1.25 AMA PRA Category 1 Credits™
Chair:
Howard L. Kaufman, MD, FACS – Rutgers Cancer Center Institute of New Jersey
1:00 p.m. – 1:05 p.m. Introduction
Howard L. Kaufman, MD, FACS – Rutgers Cancer Center Institute of New Jersey
1:05 p.m. – 1:20 p.m. Intestinal Microbiota and Relapse after Hematopoietic-Cell Transplantation  PDF  VIDEO
Jonathan Peled, MD, PhD – Memorial Sloan Kettering Cancer Center
1:20 p.m. – 1:35 p.m. Mitochondrial Biogenesis is Repressed in Tumor-Infiltrating CD8+ T Cells Resulting in Metabolic Insufficiency and T Cell Dysfunction  PDF  VIDEO
Nicole E. Scharping – University of Pittsburgh
1:35 p.m. – 1:45 p.m. Expert Discussant
Drew M. Pardoll, MD, PhD – Johns Hopkins University
1:45 p.m. – 2:00 p.m. Increased STAT3 Signaling and Decreased Suppressive Function of Regulatory T Cells are Biomarkers of Positive Patient Outcome to Nivolumab Therapy  VIDEO  PDF
David M. Woods, PhD – New York University
2:00 p.m. – 2:15 p.m. Analysis of Pharmacodynamic Biomarkers in the First In-Human Trial of GITR Co-Stimulation with the Agonist Antibody TRX-518 in Advanced Solid Cancer Patients
Roberta Zappasodi, PhD – Memorial Sloan Kettering Cancer Center
2:15 p.m. – 2:25 p.m. Expert Discussant
Jeffrey Schlom, PhD National Cancer Institute, National Institutes of Health   

Concurrent Session II: Tumor Immunology 101 (Nurse/Pharmacist Track)
 

1.5 AMA PRA Category 1 Credits™
Co-Chairs:

Satiro N. De Oliveira, MD – University of California, Los Angeles
Paul M. Sondel, MD, PhD – University of Wisconsin, Madison
1:00 p.m. – 1:05 p.m. Introduction  VIDEO
Paul M. Sondel, MD, PhD – University of Wisconsin, Madison
1:05 p.m. – 1:30 p.m. Immunology 101 for the Non-Immunologist   VIDEO
Christian Capitini, MD – University of Wisconsin, Madison
1:30 p.m. – 1:55 p.m. Basic Principles of Tumor Immunotherapy   VIDEO
Satiro N. De Oliveira, MD  – University of California Los Angeles
1:55 p.m. – 2:20 p.m. Tumor Immunotherapy on the Horizon   VIDEO
Paul M. Sondel, MD, PhD – University of Wisconsin,  Madison
2:20 p.m.– 2:25 p.m. Closing Remarks
Satiro N. De Oliveira, MD – University of California Los Angeles

Concurrent Session I: Microbiome and the Impact on Local Inflammation and Host Immunity
 

1.75 AMA PRA Category 1 Credits™
Co-Chairs: 

Lisa M. Coussens, PhD – Oregon Health and Science University
Heidi H. Kong, MD, MHSc – National Cancer Institute, National Institutes of Health
2:40 p.m. – 2:45 p.m. Introduction
Heidi H. Kong, MD, MHSc – National Cancer Institute, National Institutes of Health
2:45 p.m. – 3:10 p.m. Microbial Modulation of Mononuclear Phagocytes in Cancer Therapy
Romina Goldszmid, PhD – National Cancer Institute, National Institutes of Health
3:10 p.m. – 3:35 p.m. Influence of Microbiome on Efficacy of Anti-Cancer Chemotherapy
María Paula Roberti, PhD – Institute Gustave Roussy
3:35 p.m. – 4:00 p.m. Inflammation Fuels Microbial Carcinogenic Activities
Christian Jobin, PhD – University of Florida
4:00 p.m. – 4:15 p.m. Pre-Existing Immunity to Oncolytic Virus Potentiates its Therapeutic Efficacy
Jacob Ricca – Memorial Sloan Kettering Cancer Center
4:15 p.m. – 4:20 p.m. Closing Remarks
Lisa M. Coussens, PhD – Oregon Health and Science University

Concurrent Session II: Clinical Management (Nurse/Pharmacist Track)
 

1.75 AMA PRA Category 1 Credits™
Co-Chairs:

Matthew Burke, MBA, RN, MSN, APRN-B – Stanford Health Care
Laura S. Wood, RN, MSN OCN – Cleveland Clinic Taussig Cancer Institute
2:40 p.m. – 2:45 p.m. Introduction  VIDEO
Laura S. Wood, RN, MSN OCN – Cleveland Clinic Taussig Cancer Institute
2:45 p.m. – 3:05 p.m. Immunotherapy Agents Currently Approved for the Treatment of Cancer
Kristen Kreamer, CRNP, MSN, AOCNP, APRN-BC – Fox Chase Cancer Center
3:05 p.m. – 3:25 p.m. Assessment & Management of irAEs   VIDEO
Krista M. Rubin, MS, FNP-BC – Massachusetts General Hospital Cancer Center
3:25 p.m. – 3:45 p.m. Management of Complex Adverse Events: Case Studies   VIDEO
Brianna W. Hoffner, BA, MSN, RN, ANP-BC – University of Colorado Cancer Center
3:45 p.m. – 4:00 p.m. Incidence and Outcomes of Central Nervous System Metastasis in Metastatic Melanoma Patients Treated with Anti-PD1 Therapy
Gustavo Schvartsman, MD – University of Texas MD Anderson Cancer Center
4:00 p.m. – 4:15 p.m. Audience Question & Answer
Moderator:  Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute
4:15 p.m. – 4:20 p.m. Closing Remarks
Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute

Concurrent Session I: Diet, Exercise, Stress and the Impact on the Immune System
 

1.5 AMA PRA Category 1 Credits™
Organized in collaboration with the Society of Behavioral Medicine (SBM)

Co-Chairs:
Elizabeth  A. Repasky, PhD – Roswell Park Cancer Institute
Connie J. Rogers, PhD, MPH – Pennsylvania State University
4:50 p.m. – 4:55 p.m. Introduction
Connie J. Rogers, PhD, MPH – Pennsylvania State University
4:55 p.m. – 5:15 p.m. Changes in Energy Balance Modulate the Immune Response in Breast Cancer Risk & Progression
Connie J. Rogers, PhD, MPH – Pennsylvania State University
5:15 p.m. – 5:35 p.m. Research in Behavior in Cancer and Cancer Treatment
Dana H. Bovbjerg, PhD – University of Pittsburgh Cancer Institute
5:35 p.m. – 5:55 p.m. Effects of Behavioral Stress on the Tumor Microenvironment
Susan K. Lutgendorf, PhD – University of Iowa
5:55 p.m. – 6:10 p.m. β-Adrenergic Signaling Induced by Cool Housing Temperatures Mediates Immune Suppression and Impairs the Efficacy of Anti-PD-1 Checkpoint Blockade Immunotherapy in Laboratory Mice
Mark J. Bucsek – Roswell Park Cancer Institute
6:10 p.m. – 6:15 p.m. Closing Remarks
Elizabeth A. Repasky, PhD – Roswell Park Cancer Institute

Concurrent Session II: Adoptive Cellular Therapy vs. Bispecific Antibodies
 

1.5 AMA PRA Category 1 Credits™
Co-Chairs:

Crystal L. Mackall, MD – Stanford University
Stanley R. Riddell, MD – Fred Hutchinson Cancer Research Center
4:50 p.m. – 4:55 p.m. Introduction
Crystal L. Mackall, MD – Stanford University
4:55 p.m. – 5:15 p.m. CARs - CD19 and Beyond  VIDEO
Crystal L. Mackall, MD – Stanford University
5:15 p.m. – 5:35 p.m. Bispecific T Cell Engagers, Biology and Clinical Application
Max S. Topp, MD Universitatsklinikum Wurzburg
5:35 p.m. – 5:55 p.m. CAR Designs for Safe and Effective T Cell Therapy
Stanley R. Riddell, MD – Fred Hutchinson Cancer Research Center
5:55 p.m. – 6:10 p.m. Clinical Responses in Advanced Pancreatic Patients Treated with Bispecific Antibody Armed T Cells (BATS)
Lawrence G. Lum, MD, DSc – University of Virginia Cancer Center
6:10 p.m. – 6:15 p.m. Closing Remarks
Stanley R. Riddell, MD – Fred Hutchinson Cancer Research Center

Concurrent Session III: Emerging Technologies
 

Non-CE Session
Co-Chairs:

Edward C. Stack, PhD – PerkinElmer
David A. Zaharoff, PhD – University of North Carolina, Chapel Hill & North Carolina State University
4:50 p.m. – 4:55 p.m. Introduction  VIDEO
Edward C. Stack, PhD – PerkinElmer
4:55 p.m. – 5:20 p.m. Understanding T Cells, Macrophages, and Expression of PD-1/PD-L1 in Hodgkin's Lymphoma
Scott J. Rodig, MD, PhD – Brigham and Women's Hospital, Harvard Medical School
5:20 p.m. – 5:40 p.m. Eradication of Large Established Tumors by Combination Immunotherapy Engaging Innate and Adaptive Immunity
Darrell J. Irvine, PhD Massachusetts Institute of Technology
5:40 p.m. – 5:55 p.m. Mechanisms of Chitosan/IL-12 Immunotherapy for the Treatment of Bladder Cancer  VIDEO
Sean G. Smith  University of North Carolina - Chapel Hill & North Carolina State University
5:55 p.m. – 6:10 p.m. ImmunoMap: A Novel Bioinformatics Tool for Analysis of T Cell Receptor Repertoire Data in Model Systems and Clinical Settings  VIDEO
John-William Sidhom Johns Hopkins University
6:10 p.m. – 6:15 p.m. Closing Remarks
David A. Zaharoff, PhD University of North Carolina - Chapel Hill & North Carolina State University

Sunday, November 13, 2016
 

7:45 a.m. – 7:50 a.m.  Annual Meeting Organizer Welcome  PDF
James L. Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Health
7:50 a.m. – 8:00 a.m. Program Introduction
Howard L. Kaufman, MD, FACS – Rutgers Cancer Center Institute of New Jersey

Session I: Current Landscape of Cancer Therapy Value Models, Economic Outcomes, and the Patient Perspective

8:00 a.m. – 8:30 a.m.  Evaluation of Current Value Models   PDF  VIDEO
Peter P. Yu, MD, FACP, FASCO – Hartford HealthCare Cancer Institute
8:30 a.m. – 8:45 a.m. Cancer Immunotherapy Perspective on Current Value Models  PDF  VIDEO
Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center
8:45 a.m. – 9:05 a.m.  Economic Outcomes of Cancer Therapy: ISPOR Initiative on U.S. Value Assessment Framework
Louis Garrison, PhD, AB – University of Washington
9:05 a.m. – 9:25 a.m. Patient Perspective
Steven Silverstein, MBA – Melanoma Research Foundation
9:25 a.m. – 9:45 a.m. Patient Outcomes Perspective: Patient Reported Outcomes & Personal Cost of Cancer  VIDEO
Adam P. Dicker, MD, PhD – Thomas Jefferson University
Heather S. Jim, PhD – H. Lee Moffitt Cancer Center & Research Institute
9:45 a.m. – 10:10 a.m. Panel Discussion
Moderator:  
Howard L. Kaufman, MD, FACS – Rutgers Cancer Institute of New Jersey
Panelists:

Michael B. Atkins, MD – Georgetown-Lombardi Comprehensive Cancer Center
Adam P. Dicker, MD, PhD – Thomas Jefferson University
Lou Garrison, PhD, AB – University of Washington
Heather S. Jim, PhD – H. Lee Moffitt Cancer Center & Research Institute
Steven Silverstein, MBA – Melanoma Research Foundation
Peter P. Yu, MD, FACP, FASCO – Hartford HealthCare Cancer Institute

Session II:  Perspectives on the Value of Cancer Immunotherapy
 

10:10 a.m. – 10:30 a.m. Payor Perspective
William McGivney, PhD – McGivney Global Advisors  
10:30 a.m. – 10:50 a.m. Industry Perspective
Jon M. Wigginton, MD – MacroGenics, Inc.
10:50 a.m. – 11:10 a.m. Predictive and Companion Biomarkers
Roy S. Herbst, MD, PhD – Yale Cancer Center
11:10 a.m. – 11:55 a.m. Panel Discussion
Moderator:
Michael B. Atkins, MD –
Kirsten Axelsen, MS – Pfizer
Daniel S. Chen, MD, PhD – Genentech
Ravinder Dhawan, PhD – Merck & Co
Roy S. Herbst, MD, PhD – Yale Cancer Center
Gregory Keenan, MD – AstraZeneca
William McGivney, PhD – McGivney Global Advisors
Jon M. Wigginton, MD – MacroGenics, Inc.
11:55 a.m. – 12:00 p.m. Closing Remarks
2016 Annual Meeting
2016 Annual Meeting
2016 Annual Meeting
2016 Annual Meeting
2016 Annual Meeting

Important Dates

Thank You, Supporters!

Thank you, SITC 2016 supporters. Because of your generosity, SITC 2016 was a great success!

Interested in supporting other SITC programs? Confirm your support today!

Connect with SITC!

SITC: Join Today

SITC: TWITTERSITC: LINKEDINSITC: YOUTUBESITC: ONCOLOGY TUBE